文献速递传染病防控与疫情报告免疫规划

表达钩端螺旋体抗原的重组BCG疫苗对仓鼠钩端螺旋体病的保护作用

Protection against leptospirosis conferred by Mycobacterium bovis BCG expressing antigens from Leptospira interrogans.
PubMed 文献 · Vaccine · 2020-11-08

该研究将钩端螺旋体lipL32、lemA和ligANI基因片段克隆至BCG载体,构建四种重组BCG疫苗,皮下接种两组剂量后以5×LD50的L1-130株攻击仓鼠。所有疫苗组均对致死性攻击和肾脏定植提供保护(P<0.05),但未诱导显著体液免疫,提示细胞免疫介导保护。

要点

  • 四种重组BCG疫苗均使仓鼠在致死性攻击后100%存活且无肾脏定植。
  • 重组疫苗未诱导显著体液免疫,保护可能依赖BCG介导的细胞免疫。
  • rBCG作为活疫苗载体是控制动物钩端螺旋体病的候选策略。

核心结论

  • 四种表达钩端螺旋体抗原的重组BCG制剂在仓鼠模型中均提供100%保护,免于致死性攻击和肾脏定植。

研究设计与样本

  • 将lipL32、lemA和ligANI基因的四个片段按BioBricks策略克隆至pUP500/PpAN质粒并转化BCG Pasteur株,经Western blot检测蛋白表达。
  • 使用5组每组10只4-6周龄Golden Syrian仓鼠,分别接种rBCG(LipL32)、rBCG(LigAni)、rBCG(LemA:LigAni)、rBCG(LipL32:LemA)及野生型BCG Pasteur阴性对照。
  • 皮下接种两剂含10^6 CFU的rBCG,以5×LD50的Leptospira interrogans serovar Copenhageni L1-130攻击,观察30天至终点。
  • 通过间接ELISA评估体液免疫,通过培养和定量实时PCR评估肾脏定植。

主要发现

  • 所有疫苗接种组与阴性对照组相比均对致死性攻击和肾脏定植产生保护(P<0.05)。
  • 重组疫苗未诱导显著体液免疫,提示保护由细胞免疫介导。
  • 所有制剂在仓鼠中提供100%显著保护且无肾脏定植。

关键数值与推荐

  • 攻击剂量为5×LD50的L1-130株,观察期30天。
  • 两剂rBCG各含10^6 CFU,皮下接种。
  • 保护效果判定为免于致死性攻击和肾脏定植,统计显著性P<0.05。

临床怎么用

  • rBCG载体疫苗可能作为控制动物钩端螺旋体病的替代策略,可预防临床症状和肾脏定植。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Leptospirosis is a zoonotic disease worldwide and caused by the pathogenic spirochetes of the genus Leptospira. Bacterins make up the vaccines used against leptospirosis, but they only succeed in providing short-term and serovar-specific protection. The use of Mycobacterium bovis BCG as a live vaccine vector expressing leptospiral antigens is a promising alternative, particularly due to its adjuvant properties. Four distinct portions P1 (lipL32), P2 (ligAni), P3 (lemA:ligAni) and P4 (lipL32:lemA) of a recombinant chimera composed of the lipL32, lemA and ligANI genes from Leptospira interrogans were cloned individually according to the BioBricks® strategy in the plasmid pUP500/PpAN. These constructs were individually transformed into a BCG Pasteur strain, and protein expression was detected by Western blot. For vaccination, 5 groups of 10 Golden Syrian hamsters were used, aged 4-6 weeks - group 1, rBCG (LipL32); group 2, rBCG (LigAni); group 3, rBCG (LemA:LigAni); group 4, (LipL32:LemA); group 5, wild-type BCG Pasteur (negative control). Two doses containing 106 CFU of rBCG were administered subcutaneously, the challenge was performed with 5 × LD50 of Leptospira interrogans serovar Copenhageni L1-130, and the animals were observed for a 30-day period until the endpoint was reached. Humoral immunity was assessed via indirect ELISA, while renal colonisation was assessed by culture and quantitative real-time PCR. All vaccinated groups were protected against lethal challenge and renal colonisation, in comparison with negative control group (P < 0.05). Recombinant vaccines were not effective at inducing significant humoral immunity, which suggests the induction of cellular immunity - a characteristic of M. bovis BCG. In conclusion, all formulations provide 100% significant protection against leptospirosis in hamsters with no renal colonisation. The use of rBCG as a vaccine vector represents a promising alternative for the control of animal leptospirosis, allowing for protection against clinical signs of leptospirosis and renal colonisation.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Dorneles J, Madruga AB, Seixas Neto ACP, et al. Protection against leptospirosis conferred by Mycobacterium bovis BCG expressing antigens from Leptospira interrogans. Vaccine. 2020. PMID: 33176938. doi:10.1016/j.vaccine.2020.10.086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。